129 results
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
for multiple myeloma which comprises two independent CARs for the multiple myeloma targets, BCMA and CD19. We have developed an optimized BCMA CAR
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
interval; EFS, event-free survival; IRRC, Independent Response Review Committee; ITT, intent-to-treat; NE, not evaluable; obe-cel, obecabtagene autoleucel … marrow; CI, confidence interval; EFS, event-free survival; IRRC, Independent Response Review Committee; NE, not evaluable; SCT, stem cell transplant
NT 10-Q
AUTL
Autolus Therapeutics plc
13 May 24
Notice of late quarterly filing
9:33am
statements by an independent registered public accounting firm, as well as the general business, financial and accounting risks and other risks
S-3ASR
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
. There are certain exceptions for trading in the United Kingdom through independent agents, such as some brokers and investment managers.
All … ended December 31, 2023 have been audited by Ernst & Young LLP (PCAOB ID: 01438), independent registered public accounting firm, as set forth
S-3ASR
EX-23.1
admw q0lnf64fx5zny
28 Mar 24
Automatic shelf registration
4:10pm
S-3ASR
EX-5.1
481b5c8r 9mxph
28 Mar 24
Automatic shelf registration
4:10pm
10-K
55og7vg e7tp
21 Mar 24
Annual report
4:55pm
10-K
EX-97.1
hy0ggb
21 Mar 24
Annual report
4:55pm
10-K
EX-10.12
1d0io
21 Mar 24
Annual report
4:55pm
10-K
EX-23.1
btasm
21 Mar 24
Annual report
4:55pm
8-K
hnf57c 3s
21 Mar 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:21pm
8-K/A
EX-99.1
5fg1 xx8j
15 Mar 24
Results of Operations and Financial Condition
4:21pm
8-K
EX-99.1
kol4t xk8o
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.2
p09ooejq
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.1
ai9eoyjqy6ydzs2p
13 Feb 24
Regulation FD Disclosure
4:06pm
424B5
aziu5hu6 en2fw
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-5.1
mfw yvrn8tt
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
EX-1.1
95p9d67 7io
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
s6gtgu2
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am